Pulling SEC filings + quote and writing the call…

Entera Bio Ltd.
Next earnings Aug 6, 2026 · consensus $-0.08 EPS
Last earnings -5.1% on 2026-05-08
Conservative balance sheet (liabilities/equity 0.22x); but revenue fell -76.8% YoY.
Sources: SEC EDGAR (CIK 0001638097, latest 10-Q filed 2026-05-08) · EODHD · as of 6/24/2026, 3:11:02 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Weak on both the fundamentals and the price — little to like at the current level.
Entera Bio Ltd. shows $42.0K in FY2025 revenue (-76.8% YoY), a -27235.7% net margin, and -87.3% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $571K | $134K | $0.00 | $181K | $42.0K |
| Gross profit | $198K | $33.0K | $0.00 | $9.00K | $0.00 |
| Operating income | -$12.2M | -$13.0M | -$8.89M | -$9.59M | -$11.5M |
| Net income | -$12.2M | -$13.1M | -$8.89M | -$9.54M | -$11.4M |
| Diluted EPS | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
| Net margin | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-05-07 | Galitzer Hillel Chief Operating Officer | Award | 73.0K | |
| 2026-05-07 | Yaacov-Garbeli Dana Chief Financial Officer | Award | 58.4K | |
| 2026-05-07 | Burshtein Gregory Chief of R&D | Award | 87.6K | |
| 2026-03-09 | Germano Geno J Director | Buy | 20.0K @ $1.30 | $26.0K |
| 2026-03-05 | Ellis Sean Director | Buy | 10.0K @ $1.23 | $12.3K |
| 2026-02-12 | Rubin Steven D Director | Buy | 5.00K @ $1.49 | $7.45K |
| 2026-02-10 | Taitel Haya Director | Buy | 7.50K @ $1.48 | $11.1K |
| 2026-02-10 | Germano Geno J Director | Buy | 20.0K @ $1.49 | $29.8K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.